Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xofigo with hormone therapy and denosumab in bone-dominant metastatic breast cancer
NCT02366130Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2015
- Primary completion
- Dec 2020
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2015; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02366130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366130.